Sort   by:  
 Page size 
UnknownOngoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review.
Metastatic BRAFV600E mutated colorectal cancer is associated with poor overall survival and modest effectiveness to standard therapies. Furthermore, survival is influenced by the microsatellite status. Patients with microsatellite-stable and BRAFV600E mutated colorectal cancer ...
S-EPMC10196488 | biostudies-literature
UnknownReal world evidence reveals improved survival outcomes in biliary tract cancer through molecular matched targeted treatment.
Biliary tract cancers are rare cancers with poor prognosis due to a lack of therapeutic options, especially after the failure of first-line systemic treatment. Targeted treatments for this clinical situation are promising and have entered clinical practice. We aimed to describe the overall survival ...
S-EPMC10507096 | biostudies-literature
UnknownEarly mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity.

Background & aims

Atezolizumab/bevacizumab (atezo/bev) has revolutionized the standard of care for patients with unresectable hepatocellular carcinoma (HCC). However, only a subgroup of patients responds to atezo/bev and derives durable clinical benefit. This study aims to analyze the freque...
S-EPMC12861967 | biostudies-literature
UnknownNonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.

Background

The penetrance of leucine rich repeat kinase 2 (LRRK2) mutations is incomplete and may be influenced by environmental and/or other genetic factors. Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to reduce inflammation and may lower Parkinson's disease (PD) risk, but their...
S-EPMC7572560 | biostudies-literature
Sort   by:  
 Page size